~" Prostacyclin has strong vasodilating and antiplatelet properties. This study was performed to investigate its potential for producing profound intraoperative hypotension. Five dogs were anesthetized with morphine, nitrous oxide, and oxygen, paralyzed with pancuronium, and ventilated to a PaCO2 of 40 torr. Mean arterial blood pressure (MABP) was lowered to 40 mm Hg with an intravenous infusion of prostacyclin in 0.05 M Tris buffer (average rate of infusion 3 ---1 tzg/kg/min). Blood flow was determined using the radioactive microsphere technique. Measurements were made before and after 20, 40, and 60 minutes of hypotension; and after a 40-minute recovery period. Infusion of prostacyclin reduced MABP 63% while increasing heart rate 51%. Tachyarrhythmias occurred in all dogs, and cardiac index decreased 18%. Myocardial blood flow decreased an average of 29%, cerebral blood flow decreased 30%, cerebellar blood flow decreased 18%, and blood flow in the brain stem and spinal cord was unchanged. Cerebral metabolic rate of oxygen, determined by measuring the oxygen content of the sagittal sinus, was unchanged. Hypotension was easily induced and maintained using prostacyclin, without apparent tachyphylaxis. However, the cardiac changes caused by this drug are more severe than those accompanying hypotension induced by most other agents, and may represent a serious contraindication to its clinical use.
p
ROSTACYCLIN is a prostaglandin produced by endothelium. Physiologically it appears to balance thromboxane by inhibiting thrombus formation and producing vasodilation. 14,~6,24,34 It probably retards thrombus formation by preventing platelet adhesion and, especially, platelet aggregationJ 7'3~ In pharmacological doses, prostacyclin has been shown to be a vasodilator. 5'2~176 Its vasodilating properties and its apparent safety when given in pharmacological doses suggest that it could be a useful agent for inducing arterial hypotension during neurosurgical procedures. The purpose of this study was to document the cerebral and systemic circulatory effects of intravenous prostacyclin used to produce profound arterial hypotension.
Materials and Methods
Five mongrel dogs weighing approximately 15 kg each were used for this study. Anesthesia was induced with intravenous morphine, and nitrous oxide and oxygen (70:30). Muscular paralysis was achieved with pancuronium, 0.2 mg/kg initially and supplemented as needed. Ventilation was controlled with a pump respirator. The animals were hyperventilated and CO2 was added to the inspired gas mixture to maintain an arterial pCO2 of 40 torr. Temperature was maintained at 37~ with a warming blanket.
Blood flow was determined six times in each dog using the radioactive microsphere technique with 15 _+ 5-u spheres labeled with cerium-141, scandium-46, niobium-96, strontium-84, tin-113, and gadolinium-153. The microspheres were injected into the left ventricle utilizing a pigtail catheter inserted through the femoral artery and positioned manometrically. Blood reference samples were drawn from the right femoral and brachial arteries. At the completion of the experiment, the brain was removed and divided into cerebral hemisphere, gray and mixed gray and white samples, caudate nuclei, corpus callosum, brain stem, and cerebellum. In addition, samples of the cervical and spinal cord, temporalis and paraspinous muscles, left and right ventricles of the heart, liver, stomach, jejunum, and kidneys were removed for blood flow determinations. End-tidal CO2 was monitored continuously. Central venous and pulmonary blood pressures were measured from a SwanGanz catheter inserted through a femoral vein. This * Values are expressed as mean _+ standard error. The hypotension value is the average of the three hypotension determinations. Note the increased heart rate and decreased peripheral vascular resistance (PVR) that accompany the change in mean arterial blood pressure (MABP). CO = cardiac output; CI = cardiac index; LVEDP = left ventricle end diastolic pressure; SV = stroke volume; CVP = central venous pressure; PAP = pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; SSP = sagittal sinus pressure. Significance: ~" = p _< 0.05; ~: = p -< 0.01; w = p _< 0.001. technique was also used to measure cardiac output with the thermodilution technique. Left ventricular pressure was measured with a pigtail catheter inserted retrogradely through the femoral artery. Sagittal sinus pressure was measured from a catheter placed in the anterior sagittal sinus and directed caudally. Heart rate was derived from the electrocardiogram. These physiological parameters were recorded on an eight-channel strip chart recorder.
Immediately prior to each blood flow determination, arterial blood gases, hematocrit, and oxygen content of the sagittal sinus and arterial blood were determined. Serum potassium, chloride, and sodium were measured prior to the first and after the last blood flow determination. The cerebral metabolic rate of oygen (CMRO2)
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was estimated by multiplying the mean cerebral hemisphere blood flow by the difference between the oxygen content of systemic arterial and sagittal sinus blood. Cerebral vascular resistance was calculated by dividing the difference between mean systemic arterial pressure (MABP) and the sagittal sinus pressure by the total brain blood flow. Peripheral vascular resistance was calculated by dividing the MABP by the cardiac index (CI). The cardiac index was estimated by dividing the cardiac output (CO) by the animal's weight.
The animals were allowed to stabilize for approximately 2 hours after the induction of anesthesia, at which time two control measurements of blood flow were performed. Following the control measurements, infusion of prostacyclin in 0.05 M Tris buffer was begun. The average dose was 3 + 1 ug/kg/min (_+ standard error of the mean). The MABP was lowered to approximately 40 mm Hg and blood flow measurements were performed after 20, 40, and 60 minutes of hypotension. The prostacyclin infusion was then discontinued and another blood flow measurement was made after a 40-minute recovery period. Control values were calculated by averaging the two control determinations. Data were analyzed using the paired t-test, and values are expressed as mean + standard error.
Results
Temperature, hematocrit, and electrolytes were not significantly changed throughout the course of the experiment, except for a slight rise in serum potassium. Arterial pO2 and pCO2 remained stable during the experiment. The pH and bicarbonate decreased, however, indicating the development of a metabolic acidosis during prostacyclin-induced hypotension. This acidosis had not improved at the recovery measurement (Table 1) .
Prostacyclin infusion reduced MABP 63 % compared with control levels. This was accompanied by a marked increase in the heart rate of 51%, with frequent tachyarrhythmias in all dogs. Both heart rate and blood pressure returned to control values after the recovery period. During hypotension, CI was reduced 18% and the stroke volume was reduced 50%. Both of these parameters remained depressed during the recovery phase. During hypotension, the peripheral vascular resistance decreased 53% while cardiac work was reduced 80%. Peripheral vascular resistance overshot control values during the recovery period by 50%, while cardiac work remained 30% below control values. There were no physiologically important changes in the central venous, pulmonary, or sagittal sinus pressures (Table 2 and Fig. 1 ).
Prostacyclin hypotension reduced blood flow to the left and right ventricle 32% and 25%, respectively, and during recovery these values remained 32% and 50% below control. In contrast, blood flow to the stomach and jejunum were both elevated during hypotension 23% and 79%, respectively. During the recovery phase, these flows were reduced 49% and 5% below their original level. Blood flow to the liver was reduced 77% during hypotension and showed little change during recovery. Kidney blood flow decreased 56% during prostacyclin infusion but recovered to 41% below control level during the recovery phase. Muscle blood flow decreased 40% to 50% during hypotension, but tended to recover after the infusion was discontinued. Total cerebral blood flow (CBF) decreased 28% during the hypotensive phase and showed no subsequent change during the recovery period (Table 3 and Fig. 2) . Analysis of regional CBF demonstrated that total hemisphere, caudate nuclei, and cerebral cortex blood flows were reduced the most. Brain-stem blood flow was unaffected by prostacyclin hypotension. Recovery measurements showed that regional CBF was unchanged from the hypotensive values (Table 4 and Fig. 3) .
The CMRO~ was not statistically changed during hypotension or recovery, although there was a slight tendency for metabolism to decline over time. In contrast, cerebrovascular resistance was decreased 47 % during the hypotensive period and overshot the control value by 47% at the recovery phase (Table 5 and Fig. 4 ).
Discussion
Prostacyclin (PGI2) is a highly active compound related to the prostaglandins. It is produced mainly in the endothelial and subendothelial layers of blood yes- 
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* Values are expressed as the mean + standard error in cc/100 gm/ min. The hypotension value is the average of the three hypotension determinations. Significance: t = P -< 0.05; z~ = p _< 0.01; w = p _< 0.001. sels by the conversion of prostaglandin H2 (PGH2) and via the lungs under some conditions, but the physiological importance of this mechanism is still unclear? J~ The half-life of prostacyclin is 3 to 5 minutes, with no significant degradation occurring on passage through the lungs. There is some indication that its half-life in vitro may be somewhat longer when bound to albumin. 6,28
The action of prostacyclin includes vasodilatation and an inhibition of platelet aggregation and adhesion. The vasodilatation caused by prostacyclin varies, depending on the vascular bed involved and the dose of prostacyclin. In laboratory studies on cerebral vessels, expressed as the mean + the standard error in cc/ 100 gm/min. The hypotension value is the average of the three hypotension determinations. Note the stability of blood flow to the brain stem and cerebellum. Significance: t = P <-0.001; z~ = p _< 0.01. it has been shown that prostacyclin produces a biphasic response. Low doses cause vasodilatation, but superphysiological doses cause a vasoconstriction. 26 The effect of prostacyclin on platelets is probably mediated through an increase in cyclic adenosine monophosphate (AMP), via a modulation of adenyl cyclase. It has been shown that prostacyclin prevents platelet aggregation at very low doses, but m u c h higher doses are required to prevent platelet adhesion. '6 Most of these effects are diametrically opposed to those caused by thromboxane (TXA2), which is also a product of PGH2. Thromboxane, however, is produced via thromboxane synthetase mainly in platelets. T h r o m b o x a n e is k n o w n to cause vasoconstriction in most vascular beds and to cause platelet adhesion and aggregation. '4 Abnormalities in the balance between prostacyclin and thromboxane have been implicated, along with other abnormalities in prostaglandin metabolism, in a variety of diseases including atherosclerosis, diabetes mellitus, cerebral vasospasm following subarachnoid hemorrhage, and cerebral edema from stroke or head injury. 2' 9' 12' 22"23 ' 27 Prostacyclin has been used experimentally for a wide variety of conditions including the treatment of coronary stenosis and impending occlusion, carotid stenosis, and cerebral vasospasm.~'4'l 1,13,32,34 It has been used clinically to treat severe atherosclerotic peripheral vascular disease, with some success. These studies have shown both an i m p r o v e m e n t in pain and healing and objective evidence of improvements in blood flow to the ischemic limbs. '9,25'31 Prostacyclin has also been used for its antiplatelet aggregation action during extracorporeal bypass and thereby to reduce postsurgical bleeding due to loss of platelets. 29 The prostacyclin doses used in this study were 100 to 1000 times those used in previous clinical studies. These doses, however, had no adverse effect on hematocrit, electrolytes, or blood gases, with the exception of the production of a mild metabolic acidosis. Since hypotension itself from any pharmacological manipulation is known to produce mild metabolic acidosis, this does not appear to be a specific problem associated with prostacyclin.
The effect of prostacyclin on the heart is variable, depending on the doses used. In this study, all dogs became profoundly tachycardic during the infusion of high doses of prostacyclin. The heart rate was frequently unstable and varied widely during the hypotensive period. Despite this tachycardia, CI was reduced only 18%. The profound peripheral dilatation reduced cardiac work 80% during the hypotensive period. The blood flow to the heart showed a moderate reduction during hypotension and during the recovery period. This may largely reflect a reduction in myocardial oxygen demand due to decreased cardiac work. There is some evidence that prostacyclin is a direct coronary vasodilator, and this may have moderated the reduction in flow. However, these changes in heart rate and CI are more severe than those associated with many other pharmacological agents for producing hypotension. High doses of prostacyclin might present a risk for use in patients with preexisting heart disease. The association of subarachnoid hemorrhage with myocardial damage would make those patients undergoing operation for intracranial aneurysm particularly susceptible to this complication. Blood flow to the stomach and jejunum were both elevated, and it has been noted in a variety of other studies that these vascular beds are dilated by lower doses of prostacyclin. 2~ The reduction in flow to the liver is most likely nonspecific, as it has been reported with a number of other hypotensive agents and is also seen simply as the result of prolonged anesthesia. The 56% reduction in renal blood flow is actually somewhat less profound than is seen with some other hypotensive agents. 2~ Prostacyclin in low doses has previously been reported to be a renal vasodilator. ~5,2o Blood flow to skeletal muscle sharply decreased with prostacyclin infusion, but then tended to recover promptly after discontinuation of the infusion.
Previous investigators have reported increases in CBF due to the intravenous or intra-arterial infusion of low doses of prostacyclin. TM The high dose of prostacyclin used in this study led to a decrease in total CBF and in all regional flows except that to the brain stem. The reductions in flow seen here are not significantly different from those seen in other hypotensive agents, and in fact most likely represent a change from the profound hypotension rather than a direct effect of the prostacyclin. The fact that total CBF decreased only 28% despite a 64% reduction in MABP indicates that functional autoregulation was still present. This is further demonstrated by the 47% reduction in cerebral vascular resistance despite a very minimal change in CMRO2.
Even with its favorable changes in blood flow during profound hypotension, however, the severe effects upon the heart caused by prostacyclin in high doses are a major drawback to its clinical use. It is unclear from this study whether these cardiac effects are direct or indirect, but it appears from the literature that there are direct and reflex cardiac responses to prostacyclin. 3 '7 Research in prostaglandin metabolism in recent years has led to many discoveries that could be of potential benefit in a variety of neurosurgical problems. Cerebral edema from a variety of causes, cerebral vasospasm secondary to subarachnoid hemorrhage, and embolic and thrombotic complications of atherosclerosis may all eventually be amenable to treatment by prostaglandins or prostaglandin modulators. At the present time, research is being conducted into specific thromboxane and prostacyclin synthetase modulators and into the development of a prostacyclin analog that does not cause severe cardiac disturbances.
